Measuring Patient Quality of Life Following Treatment for Alopecia

Thadanipon, Kunlawat; Suchonwanit, Poonkiat

doi:10.2147/ppa.s282399

Cited by 17 publications

(12 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ambiguity in the wordings of some of the AASIS items likely reflects the content‐development process for this instrument, which did not include direct, qualitative patient input as recommended by current regulatory guidance on the development of PRO tools for use in clinical trial programmes. 13 The item‐generation process used to develop the AASIS involved analyses of patient responses to 125 HRQoL items in the National Alopecia Areata Registry (eg Skindex‐16, Dermatology Life Quality Index and Brief Fear of Negative Evaluation Scale) 8 , 14 and expert clinician review of these items. In the absence of qualitative patient input, the AASIS items derived from these HRQoL items may address concepts that are not salient to the experience of patients with AA.…”

Section: Discussionmentioning

confidence: 99%

Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

Winnette

Banerjee

Sikirica

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background The phase 2a ALLEGRO trial (NCT02974868) investigated the safety and efficacy of ritlecitinib (PF-06651600) and brepocitinib (PF-06700841) in adults with alopecia areata. No randomized controlled trial for alopecia areata has evaluated correlations between clinician-assessed hair loss and patient-reported outcomes. Objectives Report scores from the Alopecia Areata Symptom Impact Scale (AASIS; a patient-reported outcome tool) and explore the relationships of those scores with clinician-assessed Severity of Alopecia Tool (SALT) scores at baseline and week 24 of the ALLEGRO trial. Methods Adults with alopecia areata were randomized to ritlecitinib (n = 48), brepocitinib (n = 47) or placebo (n = 47). After 24 weeks, the mixed-effects model with repeated measures was used to calculate the active treatment groups' AASIS score least-squares mean differences. Relationships between AASIS and SALT scores at baseline and week 24 were evaluated by Pearson's correlation coefficients using pooled data. Results Baseline AASIS and SALT scores were similar among treatment groups. Both active treatment groups reported significant improvements in AASIS scores at week 24 (least-squares mean differences vs. placebo for ritlecitinib, À0.8 to À2.3; brepocitinib, À0.9 to À3.7; P < 0.05 for all). At week 24, the mean SALT scores (standard deviation) improved compared with baseline [ritlecitinib, 54.4 (40.3) vs. 89.4 (15.8); brepocitinib, 31.9 (35.7) vs. 86.4 (18.1)]. The correlation coefficients between AASIS global and subscale scores and SALT scores at week 24 ranged from 0.34 to 0.58; P < 0.05 for all. Conclusions Patients randomized to ritlecitinib or brepocitinib reported significantly improved AASIS and SALT scores at week 24 of the ALLEGRO trial compared to placebo. At week 24, medium-to-large correlations can be seen between AASIS global and subscale scores and SALT scores. Our experience with AASIS instrument highlighted several aspects that suggest new patient-reported outcome tools are needed to accurately assess patients' relevant alopecia areata related signs, symptoms and daily functioning.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

Winnette

Banerjee

Sikirica

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Patients with AA often experience major psychological impacts due to the unpredictable clinical course and variable treatment response. 6 Various immune-related comorbidities such as autoimmune thyroid diseases (AITD), vitiligo, psoriasis, and atopic diseases have been linked to AA. 7–13 …”

Section: Introductionmentioning

confidence: 99%

Intramuscular Corticosteroid Therapy in the Treatment of Alopecia Areata: A Time-to-Event Analysis

Chanprapaph¹,

Pomsoong²,

Kositkuljorn³

et al. 2022

DDDT

Self Cite

View full text Add to dashboard Cite

Introduction Intramuscular corticosteroids (IMC) have gained popularity for the treatment of severe alopecia areata (AA) in recent years; however, evidence on their efficacy and safety is still limited. Objective To evaluate the efficacy, relapse rate, and tolerability of IMC in the treatment of AA, as well as factors associated with treatment outcomes. Methods Time-to-event analysis was performed on patients with severe, extensive, or rapidly progressive AA receiving IMC. The IMC regimen comprised triamcinolone acetonide 20–40 mg/mL injected every 4–6 weeks. The evaluated outcomes included initial (25% regrowth), significant (75% regrowth), and complete hair regrowth (100% regrowth). Relapse and adverse events were also noted. Factors associated with treatment outcomes and relapse were analyzed using the Cox proportional hazards model. Results A total of 101 patients were eligible for analysis. Significant hair regrowth was obtained in 80.2% of the patients (n = 81), in a median time of 3.4 months (95% confidence interval [CI] = 2.9–4.4). Complete hair regrowth was achieved in 48.5% of the subjects (n = 49), and relapse was observed in 47.5% (n = 48). Acneiform eruption was the most common adverse effect. Multivariable analysis revealed that nail involvement was a negative predictor of significant hair regrowth (adjusted hazard ratio [HR] = 0.04, 95% CI = 0.01–0.55; P = 0.015), whereas duration of AA longer than 6 months was associated with disease recurrence (adjusted HR = 4.02, 95% CI = 1.52–4.66; P = 0.005). Conclusion This study demonstrated the efficacy and safety of IMC in the treatment of severe or active AA; however, the relapse rate remained relatively high after discontinuation of the therapy. Nail involvement was a negative predictor of significant hair regrowth, while disease duration longer than 6 months predicted AA relapse.

show abstract

“…Alopecia is a common dermatological disorder affecting the population worldwide. The condition is highly associated with psychological distress and impacts patients’ quality of life ( 1 ). Alopecia manifests varyingly and is categorized into non-cicatricial (non-scarring) and cicatricial (scarring) alopecias, which include several disorders ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A systematic review

et al. 2022

Self Cite

View full text Add to dashboard Cite

BackgroundImmune-mediated alopecias (IMAs), a group of hair disorders associated with immunological reactions, remain a therapeutic challenge since available treatments are generally unfavorable with potential side effects. Platelet-rich plasma (PRP) has been recently proposed as a treatment option based on several limited-quality studies; however, there is no systematic evaluation of PRP efficacy on IMAs in the literature.ObjectiveTo assess PRP’s effects in treating IMAs using a systematic review.MethodsElectronic searches were conducted using PubMed, Embase, Scopus, and Cochrane Library databases. A search strategy was designed to retrieve all studies exploring PRP in treating IMAs, including alopecia areata (AA) and primary cicatricial alopecias (PCAs). In addition, all randomized and non-randomized studies reporting subjective and/or objective outcomes of alopecia treatment with PRP were included.ResultsThirty-two studies were included, comprising 621 patients with AA and 19 patients with PCAs. PRP had superior efficacy as monotherapy in five studies, comparable to intralesional corticosteroids in six studies in AA treatment. In addition, in the analysis of PCAs, including lymphocytic and neutrophilic subtypes, PRP was efficacious in alleviating disease progression in nine studies.ConclusionPRP is considered a promising treatment for AA and PCAs in patients who experienced unfavorable outcomes from conventional treatment. However, its clinical application remains to be standardized, and its recommendation as a treatment for IMAs could not be ascertained due to a lack of high-quality evidence.Systematic review registration[https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=353859], identifier [CRD42022353859].

show abstract

Measuring Patient Quality of Life Following Treatment for Alopecia

Cited by 17 publications

References 82 publications

Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib

Intramuscular Corticosteroid Therapy in the Treatment of Alopecia Areata: A Time-to-Event Analysis

Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A systematic review

Contact Info

Product

Resources

About